Repetitive transcranial magnetic stimulation systems: special controls guidance
Device regulatory framework and risk controls.
Evidence memo
rTMS
Also tracked as: Repetitive transcranial magnetic stimulation, TMS
A noninvasive neuromodulation modality with FDA-cleared device contexts and ongoing optimization questions.
Approved specific use Approved specific use
Evidence status
Clinically established in specific contexts. Evidence level: Approved specific use.
Claim being evaluated
Which rTMS settings, targets, and patient groups are supported by cleared indications and clinical evidence.
Why people care
It offers a non-drug intervention for certain neuropsychiatric contexts and is now part of mainstream treatment infrastructure.
Signal so far
Regulatory and clinical evidence support specific cleared uses; personalization and expanded indications remain active research areas.
Biggest unknown
Response prediction, durability, targeting optimization, and the boundary between cleared use and experimental settings.
Safety/regulatory boundary
Device clearance is context-specific. Claims should stay tied to condition, device, and treatment-setting evidence.
Watch next
Personalized targeting data, durability studies, and new device clearances.
Evidence interpretation
Established in specific clinical contexts and still evolving technically.
References
Brain stimulation therapies
Patient-facing overview of FDA-cleared rTMS contexts.